Guardant Health Boosts 2026 Revenue Guidance on Strong Oncology and Screening Growth
Event summary
- Guardant Health reported $301.7M in Q1 2026 revenue, up 48% YoY, driven by 47% growth in oncology tests and 600% increase in screening revenue.
- Oncology revenue grew 36% to $205.0M, while screening revenue surged to $41.6M from $5.7M in the prior year period.
- The company raised its 2026 revenue guidance to $1.30–1.32B, up from the previous $1.25–1.28B range.
- Guardant Health launched Shield Multi-Cancer Detection (MCD) in Asia through a partnership with Manulife.
- The company received FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU.
The big picture
Guardant Health's strong Q1 2026 performance highlights the growing demand for precision oncology and early cancer detection solutions. The company's strategic partnerships and FDA approvals position it well in the competitive oncology market, but it must balance rapid growth with operational efficiency to maintain its leadership position. The raised revenue guidance reflects optimism about sustained volume growth and expanding commercial reach.
What we're watching
- Revenue Growth
- Whether Guardant Health can sustain its strong revenue growth trajectory, particularly in the oncology and screening segments, as it scales its commercial infrastructure.
- Partnership Expansion
- The pace at which Guardant Health can leverage its partnerships with Quest, Manulife, and others to drive further adoption of its Shield and oncology tests.
- Operational Efficiency
- How the company manages its increasing operating expenses while maintaining profitability, given its current net loss position.
Related topics